Cancer Biotherapy and Radiopharmaceuticals

Our screening does not flag Cancer Biotherapy and Radiopharmaceuticals. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.

Per our venue index, Cancer Biotherapy and Radiopharmaceuticals appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Cancer Biotherapy and Radiopharmaceuticals are cited about 1.1 times each within two years of publication, and Scimago places it in Q2, with an h-index of 78. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Cancer Biotherapy and Radiopharmaceuticals is Q2 in 1 of its 5 subject categories, Q3 in 3 and Q4 in 1. By category: Radiology, Nuclear Medicine and Imaging: Q2, #171 of 360; Pharmacology: Q3, #200 of 339; Oncology: Q3, #279 of 426; Medicine (miscellaneous): Q3, #1,323 of 2,517; Cancer Research: Q4, #188 of 235. Its best category quartile is Q2. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Cancer Biotherapy and Radiopharmaceuticals is cited about 1.1 times per paper over two years, with an h-index of 78.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Cancer Biotherapy and Radiopharmaceuticals. The open equivalent is its best Scimago quartile, Q2 in Radiology, Nuclear Medicine and Imaging, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.